Provided by Tiger Trade Technology Pte. Ltd.

Corgi NVO 2x Daily ETF

13.75
-0.0756-0.55%
Post-market: 13.820.0756+0.55%16:10 EDT
Volume:16
Turnover:225
Market Cap:206.22K
PE:- -
High:13.75
Open:13.82
Low:13.75
Close:13.82
52wk High:27.19
52wk Low:13.75
Shares:15.00K
Float Shares:15.00K
Volume Ratio:0.18
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Yesterday

Novo Nordisk Says FDA Review of Hemophilia Drug is Hitting Delays

Dow Jones
·
8 hours ago

Novo Nordisk Tests Zenagamtide Dosing to Sharpen Its Obesity Drug Pipeline

TIPRANKS
·
14 hours ago

Novo Nordisk A/S Series B Stock Falls Friday, Underperforms Market

Dow Jones
·
14 hours ago

Moderately bullish activity in Novo Nordisk with shares up 0.39%

TIPRANKS
·
Yesterday

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Yesterday

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?

Options & Short Sell
·
Oct 01

Moderately bullish activity in Novo Nordisk with shares down 1.06%

TIPRANKS
·
Oct 01

Novo Nordisk Opens a New Front in Cardiometabolic Care With Early-Stage Anti-Inflammatory Study

TIPRANKS
·
Oct 01

Novo Nordisk Tests Cagrisema Switch Strategy to Strengthen Its Diabetes Franchise

TIPRANKS
·
Oct 01

Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Oct 01

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30

Novo Nordisk announces new data on CagriSema

TIPRANKS
·
Sep 30

Patients Switching to Novo Nordisk's Wegovy Pill from Shots Lose More Weight in Real-World Study

Reuters
·
Sep 30

2026 Nobel Prize Preview: Scientists Behind GLP-1 Weight-Loss Drugs Emerge as Leading Contenders

Deep News
·
Sep 30

Novo Says Ozempic Cuts Risk of Major Cardiovascular Events

Reuters
·
Sep 29

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 29

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live
·
Sep 29

Lilly's Zepbound (Tirzepatide 10 Mg and 15 Mg) was Associated with More Weight Loss than Wegovy Hd (Semaglutide Injection 7.2 Mg) in a New Indirect Treatment Comparison

THOMSON REUTERS
·
Sep 29